High levels of serum glypican-1 indicate poor prognosis in pancreatic ductal adenocarcinoma.

Cong-Ya Zhou, Yi-Ping Dong, Xiao Sun, Xin Sui, Hong Zhu, Ya-Qin Zhao, Yuan-Yuan Zhang, Clifford Mason, Qing Zhu, Su-Xia Han

Cancer medicine 2018 Nov

filter terms:

Carbohydrate antigen 19-9 (CA19-9) fails to demonstrate the predictive value for early detection pancreatic ductal adenocarcinoma (PDAC). Glypican-1 (GPC1+) exosomes may serve as a noninvasive diagnostic tool to detect early stages of PDAC. Therefore, it is necessary to explore the serum GPC1 levels and determine whether serum GPC1 serves as a novel biomarker for PDAC patients. Blood samples were collected from 156 patients with PDAC, 199 non-cancer controls, and 240 patients with other cancers. Serological levels of GPC1 were examined by enzyme-linked immunosorbent assay (ELISA). Finally, a 5-year follow-up was monitored to evaluate the correlation between serum GPC1 levels and overall survival in 156 patients with PDAC. The results suggested that levels of serum GPC1 and CA19-9 were higher in PDAC patients than that of controls (P < 0.05). Serum GPC1 levels in PDAC were different from those in gallbladder carcinoma (P < 0.001), colorectal carcinoma (P < 0.001), gastric carcinoma (P < 0.001), and prostate cancer (P < 0.001), but not hepatocellular carcinoma (P = 0.395) and cholangiocarcinoma (P = 0.724). Receiver operating characteristic curve (ROC) analysis showed that serum CA19-9 was significantly better than serum GPC1 in distinguishing PDAC patients from the controls (AUC, 95% CI: 0.908, 0.868-0.947 vs 0.795, 0.749-0.841, respectively). The serum GPC1 cannot be used as a serum diagnostic biomarker for PDAC patients. The level of serum GPC1 decreased 2 days after surgery (P = 0.001), which were not different from serum GPC1 levels in healthy control (P = 0.381). The overall survival rate was shorter in patients with high levels of serum GPC1 compared to those with low levels of serum GPC1 (log-rank = 5.16, P = 0.023). Taken together, the results indicate that high levels of serum GPC1 predict poor prognosis in PDAC patients. Serum GPC1 may be a prognosis factor for PDAC patients. © 2018 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

Citation

Cong-Ya Zhou, Yi-Ping Dong, Xiao Sun, Xin Sui, Hong Zhu, Ya-Qin Zhao, Yuan-Yuan Zhang, Clifford Mason, Qing Zhu, Su-Xia Han. High levels of serum glypican-1 indicate poor prognosis in pancreatic ductal adenocarcinoma. Cancer medicine. 2018 Nov;7(11):5525-5533